Menu
Enrolling by invitation NCT06880042

COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Early Phase I Interventional Vitiligo - Macular Depigmentation Tacrolimus

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Tacrolimus, Calcipotriol.
Who it may be relevant to
Registry conditions: Vitiligo - Macular Depigmentation, Tacrolimus. Basic parameters: 15 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Pakistan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Detailed description

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Interventions

  • Drug Tacrolimus
    Tacrolimus is calcineurin inhibitor that will act as immunomodulator
  • Drug Calcipotriol
    Calcipotriol is a vitamin D analogue that will act as immunomodulator

Primary outcome measures

  • VASI improvement upto 50% [Time frame: 3 months]

Eligibility criteria

Inclusion criteria

\- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months

Exclusion criteria

  • • Pregnant or lactating female patients.
  • Skin malignancy or any other malignant skin condition.
  • Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo.
  • Prior history of allergy to tacrolimus or calcipotriol.
  • Other form of treatment for vitiligo within at least 1 month.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Pakistan · 1 center
  • Lahore general.hospital — Lahore

Identifiers

NCT: NCT06880042 · LGH

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗